Novartis | NVS - Trade Creditors



Novartis reported $4.51B in Trade Creditors for its fiscal quarter ending in June of 2025.


Trade Creditors Change Date
AbbVie 2.94B 2.66B Dec/2024
Amgen USD 18.03B 15.63B Jun/2025
AstraZeneca 23.99B 1.44B Jun/2025
Bausch Health Companies USD 627M 7M Jun/2025
Biogen USD 408.4M 16.9M Jun/2025
Bristol-Myers Squibb USD 5.43B 1.42B Jun/2025
Canopy Growth CAD 24.08M 4.84M Jun/2025
Corcept Therapeutics USD 23.52M 4.42M Jun/2025
Drreddys Laboratories INR 37.46B 1.44B Jun/2025
Eli Lilly USD 4.08B 633.7M Jun/2025
Gilead Sciences USD 582M 155M Jun/2025
GlaxoSmithKline 14.82B 329M Jun/2025
Glaxosmithkline 13.65B 10.19B Jun/2025
J&J USD 9.54B 766M Mar/2025
Merck USD 4.04B 261M Jun/2025
Novartis USD 4.51B 245M Jun/2025
Novartis USD 4.51B 66M Jun/2025
Pacira USD 30.12M 6.95M Jun/2025
Perrigo USD 489M 13.3M Jun/2025
Pfizer USD 5.17B 74M Jun/2025
Prestige Brands USD 22.21M 3.28M Jun/2025
Roche Holding 4.35B 828M Dec/2024
Sanofi 7.08B 14.54B Jun/2025
Sanofi 7.08B 476M Jun/2025
Supernus Pharmaceuticals USD 8.22M 1.14M Jun/2025
Zoetis USD 508M 88M Jun/2025